CBLC — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25183027	0.64	3/20
SCHEMBL25173586	0.55	3/20
SCHEMBL25179596	0.55	3/20
SCHEMBL25179597	0.55	3/20
SCHEMBL25179657	0.55	3/20
SCHEMBL25179658	0.55	3/20
SCHEMBL25180082	0.55	3/20
SCHEMBL25182947	0.55	3/20
SCHEMBL25186663	0.55	3/20
SCHEMBL25186664	0.55	3/20
SCHEMBL25186882	0.55	3/20
SCHEMBL25192814	0.55	3/20
SCHEMBL25180197	0.54	3/20
SCHEMBL25180198	0.54	3/20
SCHEMBL25180216	0.54	3/20
SCHEMBL25180217	0.54	3/20
SCHEMBL25186641	0.54	3/20
SCHEMBL25179683	0.54	3/20
SCHEMBL25179684	0.54	3/20
SCHEMBL25179685	0.54	3/20

Clinical trials — most relevant to CBLC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
A Window of Opportunity Study of Black Raspberry for Patients With HNSCC	EARLY_PHASE1	WITHDRAWN
BRCA1 Haploinsufficiency and Gene Expression	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management	nan	COMPLETED
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families	nan	COMPLETED
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.	nan	COMPLETED
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
CML Pediatric ITK Response According to Molecular Identification at Diagnosis	nan	RECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Novel Genetic Disorders of the Immune System	nan	RECRUITING
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
CDH1 Germline Mutations in Lobular Breast Cancer	nan	COMPLETED
Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents	nan	AVAILABLE
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer	nan	COMPLETED
Nutritional Ketosis: a Novel Metabolic Strategy to Treat Lymphedema Patients?	nan	RECRUITING
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction	nan	RECRUITING
B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment	nan	UNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination.	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a CBLC binder may also engage these)

Protein	Name	Similarity
Q80XL1	—	0.992	Q80XL1 →
G3V8H4	—	0.987	G3V8H4 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.979	landscape →
A2VDW6	—	0.979	A2VDW6 →
Q9Y613	—	0.978	Q9Y613 →
Q91W40	—	0.978	Q91W40 →
Q8VDP3	—	0.977	Q8VDP3 →
Q6F5E8	—	0.977	Q6F5E8 →
Q68G30	—	0.976	Q68G30 →
Q8TDZ2	—	0.976	Q8TDZ2 →
Q924T7	—	0.975	Q924T7 →
Q9D6J4	—	0.975	Q9D6J4 →
O94810	—	0.974	O94810 →
Q8K045	—	0.974	Q8K045 →
Q9BST9	—	0.974	Q9BST9 →
O70248	—	0.974	O70248 →
PKN3	Serine/threonine-protein kinase N3	0.974	landscape →
Q8R5F8	—	0.974	Q8R5F8 →
F1MH07	—	0.974	F1MH07 →
Q3V3V9	—	0.973	Q3V3V9 →
Q8TE68	—	0.973	Q8TE68 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.973	landscape →
D3ZBP4	—	0.972	D3ZBP4 →
P70218	—	0.972	P70218 →
O96018	—	0.972	O96018 →
Q6V7V2	—	0.970	Q6V7V2 →
Q643R3	—	0.970	Q643R3 →
Q92502	—	0.970	Q92502 →
Q99ML2	—	0.970	Q99ML2 →
MUS81	Structure-specific endonuclease subunit MUS81	0.970	landscape →